Early-Onset Liver Fibrosis Due to Primary Hepatitis C Virus Infection Is Higher Over Time in HIV-Infected Men

TO THE EDITOR—We were pleased to read the recent report by Vogel et al [1] of their study undertaken in response to our findings of rapid onset fibrosis during primary hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)–infected men [2]. Their study, plus the recent publication of the liver biopsy results of Bottieau et al [3], seems to cement that this unexpected outcome is a true consequence of primary HCV infection in HIV-infected men. We disagree, however, that their results using transient elastography demonstrate a sharp decrease in the fibrosis progression rate (FPR) to a clinically unimportant level soon after the primary HCV infection period has waned.

Transient elastography measures liver stiffness, not fibrosis per se. In patients with new viral hepatitis [4] and in patients with chronic HCV infection [5], inflammation contributes significantly to the liver stiffness score. Patients with biopsies showing as little as stage 0–1 fibrosis but with higher alanine transaminase (ALT) levels had a high rate of spuriously attributed cirrhosis (stage 4) [5]. Because Vogel et al did not have liver biopsies of these patients, they could not adjust for this effect, and they thereby vastly overestimated the stage of fibrosis (and therefore the FPR) during early primary HCV infection. Then, when they calculated FPR in the subgroup of just 5 patients who were assessed at later times when inflammation and ALT were much lower, they found a much lower FPR.

To better address this issue, in continuation of our previously reported study, we performed a total of 29 liver biopsies of HIV-infected men with primary HCV infection (including the 11 reported previously [2]). Figure 1 shows a plot of histological stage against the time from first-noted ALT elevation (which coincided with the clinical presentation in >90% of cases). The results of this analysis show that higher histopathological stage of fibrosis was associated with increasing length of HCV infection (regression analysis, \( P = .04 \)). These data further reinforce that in HIV-infected men there is rapid onset of fibrosis in the first 1–2 years after primary HCV infection that does not appear to resolve. Due to the same short time of follow-up as in the Vogel et al study, we cannot determine from these data the rate at which this fibrosis does or does not continue to accumulate. What happens in the subsequent 2–5 years will determine how clinically meaningful these findings end up being. But with a baseline of stage 2 fibrosis in most men immediately following the primary HCV infection, even a relatively low FPR would lead to cirrhosis more rapidly than in most clinical settings. We are optimistic that with the continued development of new HCV treatments we may be able cure nearly everyone with HCV infection within 5–10 years—but that may be too long for some of these patients. We therefore encourage Vogel and colleagues to perform long-term follow-up of their enrolled patients as we plan to do with ours so we can directly monitor liver disease progression in these patients.

Note

Potential conflicts of interest. A. D. B. has received institutional grant support from the National Institutes of Health. D. T. D. has received institutional grant support from Genentech; consulting fees from Genentech, Roche, Boehringer Ingelheim, Idenix, Bristol-Myers Squibb, and Gilead; and fees for participation in review activities from Tobira. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Daniel S. Fierer,1 Michael P. Mullen,1
Douglas T. Dieterich,1 M. Isabel Fiel,2 and
Andrea D. Branch1

Departments of 1Medicine, and 2Pathology, Mount Sinai School of Medicine, New York, New York

References


Correspondence: Daniel Seth Fierer, MD, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, Box 1009, New York, NY 10029 (Daniel.Fierer@mssm.edu).

Clinical Infectious Diseases 2012;55(6):887–8
© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cis538